(Q38028411)

27 August 2017

title

Management of adverse events of targeted therapies in normal and special patients with metastatic renal cell carcinoma (English)

1 reference

27 August 2017

author name string

María José Méndez-Vidal

1

1 reference

27 August 2017

Esther Martínez Ortega

2

1 reference

27 August 2017

Alvaro Montesa Pino

3

1 reference

27 August 2017

Begoña Pérez Valderrama

4

1 reference

27 August 2017

Ruth Viciana

5

1 reference

27 August 2017

publication date

1 September 2012

1 reference

Cancer and Metastasis Reviews

27 August 2017

published in

1 reference

27 August 2017

volume

31 Suppl 1

1 reference

27 August 2017

page(s)

S19-27

1 reference

https://scigraph.springernature.com/pub.10.1007/s10555-012-9355-y

27 August 2017

exact match

0 references

cites work

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9355-Y

Reversible posterior leucoencephalopathy syndrome associated with sunitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9355-Y

Reversible posterior leucoencephalopathy syndrome in an elderly male on sunitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9355-Y

Sunitinib in clinical practice: the expanded access program for metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9355-Y

Sorafenib in advanced clear-cell renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9355-Y

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9355-Y

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9355-Y

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9355-Y

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9355-Y

Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9355-Y

Impact of the incorporation of tyrosine kinase inhibitor agents on the treatment of patients with a diagnosis of advanced renal cell carcinoma: study based on experience at the Hospital Universitario Central de Asturias.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9355-Y

Megestrol acetate in cachexia and anorexia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9355-Y

mTOR inhibition by rapamycin prevents beta-cell adaptation to hyperglycemia and exacerbates the metabolic state in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9355-Y

Pharmacologic management of the older patient with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9355-Y

A new reality: achieving cholesterol-lowering goals in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9355-Y

Targeting mTOR in renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9355-Y

A systematic review and meta-analysis of the pharmacological treatment of cancer-related fatigue

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9355-Y

Safety and Efficacy of Sorafenib in Elderly Patients Treated in the North American Advanced Renal Cell Carcinoma Sorafenib Expanded Access Program

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9355-Y

Sunitinib in metastatic renal cell carcinoma patients with brain metastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9355-Y

Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9355-Y

Sunitinib and sorafenib in metastatic renal cell carcinoma patients with renal insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9355-Y

Safety and efficacy of molecularly targeted agents in patients with metastatic kidney cancer with renal dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9355-Y

Pharmacokinetics of sunitinib malate in subjects with hepatic impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9355-Y

Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9355-Y

10.1007/S10555-012-9355-Y

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

27 August 2017

1012523961

0 references

1 reference